



Published in final edited form as:

*Brain Pathol.* 2009 January ; 19(1): 121–131. doi:10.1111/j.1750-3639.2008.00236.x.

## Brain Tumor Susceptibility: the Role of Genetic Factors and Uses of Mouse Models to Unravel Risk

**Karlyne M. Reilly, Ph.D.**

Mouse Cancer Genetics Program, National Cancer Institute-Frederick, Frederick, Md.

### Abstract

Brain tumors are relatively rare but deadly cancers, and present challenges in the determination of risk factors in the population. These tumors are inherently difficult to cure because of their protected location in the brain, with surgery, radiation and chemotherapy options carrying potentially lasting morbidity for patients and incomplete cure of the tumor. The development of methods to prevent or detect brain tumors at an early stage is extremely important to reduce damage to the brain from the tumor and the therapy. Developing effective prevention or early detection methods requires a deep understanding of the risk factors for brain tumors. This review explores the difficulties in assessing risk factors in rare diseases such as brain tumors, and discusses how mouse models of cancer can aid in a better understanding of genetic risk factors for brain tumors.

### Keywords

astrocytoma; genetic risk factors; glioblastoma multiforme; mouse models; neurofibromatosis; peripheral nerve sheath tumors

---

## ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE

The debate over the past decade on whether cell phone use increases brain tumor risk highlights the difficulties in identifying risk factors for brain tumorigenesis. Multiple studies have produced conflicting results, and although it is now accepted that the risk of developing a brain tumor from cell phone use is likely negligible (1,25,34,51,66), the few studies showing an effect of cell phones continue to raise concerns in the general population. Although risk factors and causes of many common cancers have now been established (<http://www.cancer.gov/cancertopics/prevention-genetics-causes>), understanding the factors that contribute to brain tumors remains elusive.

## DISEASE RISK FACTORS

There are multiple types of risk factors governing disease susceptibility. These include behavioral risk factors, such as choosing to smoke or excessive alcohol consumption, environmental risk factors, such as exposure to chemical carcinogens or radiation, biological risk factors, such as puberty or aging and genetic risk factors, such as inheritance of tumor suppressor mutations or susceptibility alleles of modifier genes. These different risk factors form a spectrum of what people can control to what they cannot control, with behavioral risk factors being the easiest to control and biological risk factors being impossible to control.

---

Journal Compilation © 2008 International Society of Neuropathology

**Corresponding author:** Karlyne M. Reilly, PhD, Mouse Cancer Genetics Program, National Cancer Institute-Frederick, West 7th Street at Fort Detrick, PO Box B, Frederick, MD 21702 (kreilly@ncifcrf.gov).

Furthermore, different types of risk factors interact. For example, the behavioral risk factor of smoking likely interacts with genetic variability in the population that determines how easily a person becomes addicted to cigarettes. Similarly, wearing sunscreen is a behavioral factor that reduces risk, counteracting the environmental risk of UV exposure. By understanding different types of risk factors, it is hoped that protective factors that are controllable (such as wearing sunscreen) can be developed to counteract risk factors that are uncontrollable (such as UV exposure). In the case of brain tumors, this might include increased screening for early detection of tumors in individuals at higher risk because of genetic susceptibility. While an individual's exposure to behavioral and environmental risk can be difficult to study and can change at different times of life, genetic risk factors are expected to be stable in the individual over their lifetime. This article will focus primarily on genetic determinants of brain tumor risk because an individual's genetic background forms the foundation against which all other risk factors interact.

## GENETIC RISK FACTORS FOR BRAIN CANCER

Although very little is known about the genetic risk factors for brain cancer, a few factors have been identified thus far. Brain tumors are associated with several familial cancer predisposition syndromes. These include Li-Fraumeni syndrome, neurofibromatosis, tuberous sclerosis and Turcot's syndrome. In these syndromes, individuals inherit a germline mutation in a tumor suppressor gene. Tumors initiate when the remaining copy of the tumor suppressor is mutated or silenced, giving rise to cells with a growth advantage. Because tumorigenesis requires the accumulation of multiple mutations in cells, these individuals have an increased tumor risk because all cells carry an initial mutation. Li-Fraumeni syndrome is caused by mutations in the cell checkpoint genes *TP53* (40) and *CHEK2* (4). Turcot's syndrome is caused by mutations in genes involved in DNA repair (24). It is likely that in Li-Fraumeni syndrome and Turcot's syndrome the risk for brain tumors is increased by an increased rate of DNA mutation leading to uncontrolled growth. Neurofibromatosis is caused by mutations in *NF1* or *NF2* (20,29) and tuberous sclerosis is caused by mutations in *TSC1* or *TSC2* (2,36). *NF1*, *NF2*, *TSC1* and *TSC2* are all involved in down regulation of growth promoting signal transduction pathways in the cell. It is therefore likely that in neurofibromatosis and tuberous sclerosis, the risk for brain tumors is increased because brain cells are primed for excessive growth and then develop additional mutations allowing cancer to form.

In addition to known familial cancer predisposition syndromes, it has also been observed that brain tumors can cluster within families [see (45) for review]. Familial clustering can be because of both genetic and environmental factors, as families often share common environmental exposures in addition to common genes. Modeling of the inheritance pattern of familial glioma suggests that at least in some cohorts, genetic factors play a role in susceptibility (15,41,42). Segregation analysis of 297 families in Sweden suggested that recessive genes may contribute to familial glioma, although a multifactorial model was not excluded (41). However, homozygosity mapping in a study of seven glioma families in Sweden did not identify any common homozygous alleles (44). Segregation analysis of 639 families in the United States and Canada found evidence for a multifactorial Mendelian model, and suggested that familial glioma is affected by multiple low penetrance genes (15). In contrast, a study of 396 families in Iceland found no evidence for increased risk of gliomas in families, although the authors cite several limitations to the study including small sample size (53).

Although evidence for a genetic risk component in brain tumors has been demonstrated, efforts to identify the underlying genes have had little success. A study of seven families in Sweden found weak linkage to chromosome 1q23 (logarithm of the odds (LOD) = 1.0517)

(44). In a study of 15 families in Finland, linkage for susceptibility to glioma was found on four chromosomes, 1q25.1, 6q27, 8p21.3 and 15q26.2, with chromosome 15 showing the most significant linkage. Because the linked region on chromosome 15 covers 40 cM, it was not possible to identify genes in this study (58). These studies are severely hampered by the fact that brain tumors are rare and different brain tumor types often need to be pooled together in studies, possibly diluting out significant effects on specific brain tumor histologies. To begin to address these issues, the GLIOGENE international consortium has recently formed to collect large numbers of brain tumor cases (45).

Because of the difficulties in using unbiased screens for genetic risk factors, many investigators have turned to candidate approaches to test for susceptibility genes. One of the earliest gene families to be examined was the glutathione S-transferase (GST) family of genes because of their role in detoxifying environmental carcinogens. Studies attempting to link specific GST polymorphisms to brain tumor risk have given conflicting results, with most studies finding no significant link between GST genotype and brain tumor risk (37,54,69,73). Patients carrying a combination of the germ-line genotype *GSTP1*\*A/\*A and *GSTM1* null were shown to have an increased survival, but also have greater adverse effects in response to chemotherapy (54). A second candidate approach has been to examine the role of genes involved in DNA repair, such as p53 and XRCC (6,35,43,46,77). These studies have also shown mixed results, with polymorphisms in p53 showing increased risk in glioblastoma in one study (46), but not another (77), and polymorphisms in *XRCC7* being associated with risk for glioma (77). Recently, a polymorphism in the apoptosis gene *Caspase 8* has also been shown to be associated with increased glioma risk, although in four out of the five case control studies examined, this association was not statistically significant (5). An observed inverse relationship between asthma and glioma (81) has led investigators to examine polymorphisms in genes associated with immune response and inflammation. Studies of the association of polymorphisms in *IL13* and *IL4R* with glioblastoma risk have produced conflicting results (67,68,80).

The studies to link candidate genes to brain tumor risk overall have yielded mixed results, pointing out the difficulty of understanding the genetic basis of brain tumor risk, even when evidence exists for this genetic risk being important. The difficulty in finding genetic risk factors stems from the limited number of brain tumor patients available for these studies, the possibility for necessary interactions of different genetic factors, such that a single candidate factor does not show significant linkage, and the possibility that genetic factors interact with environmental risk factors that are not uniform across different populations and different studies. In essence, this boils down to too many variables and not enough subjects to determine statistical significance. While the GLIOGENE consortium seeks to build a large study population, this may not entirely solve the problem if confounding variables and heterogeneity in the population, both at the genetic and environmental level, are the issue.

## MOUSE MODELS OF BRAIN CANCER TO DISSECT ISSUES OF HETEROGENEITY

When studying genetic risk factors in human populations, one must consider and control for many confounding variables. Mouse models of human cancer allow one to start with a relatively homogeneous system and layer on complexity in a controlled way. This allows one to determine genetic risk factors in an unbiased screen using fewer subjects than would be possible in a human study. Genetic risk factors that are identified in mice can then be tested for association in human populations using more straightforward candidate approaches. Mouse models of brain cancer can be bred under relatively constant environmental conditions with a constant diet and a well-controlled genetic background to isolate genetic factors from environmental factors. Once the genetic factors are well

understood, environmental factors can be introduced into the experiment, for example by feeding mice a high-fat diet or exposing them to pathogens or carcinogens, to determine the effects on cancer risk. Mouse models of skin cancer, lung cancer, colon cancer, plasmocytoma, teratoma, and breast cancer metastasis have already been used to identify modifier genes of cancer susceptibility (13,16,19,21,55,64,84,85). Ongoing experiments are using a mouse model of astrocytoma and secondary glioblastoma to identify modifiers of brain cancer (61).

The power of mapping modifiers of brain tumors in mouse lies in the ability to generate large numbers of homogeneous individuals. A mouse model of astrocytoma and secondary glioblastoma has been generated by combining mutations in *Nf1* and *Trp53* on the same chromosome of the mouse (60). Because the mutations are tightly linked on the same chromosome, they are inherited as a single mutation, resulting in near Mendelian inheritance ratios. These mice develop brain tumors with high penetrance in the population, such that in a population of mutant progeny, up to 70% of animals will develop a brain tumor (Figure 1) with many of the characteristics of human astrocytoma and glioblastoma (Figures 1 and 2). This combination of high penetrance and simple genetics means that large numbers of mice developing brain tumors can be generated relatively easily for studies of brain tumor risk.

The *Nf1* gene encodes the protein neurofibromin that acts as a rasGAP protein to downregulate active ras signaling (3,22,26,47,82,83). The gene is mutated in the disease NF1 in which patients develop many benign tumors of the nervous system and are at increased risk for developing astrocytomas, glioblastomas and malignant peripheral nerve sheath tumors. *Nf1* has recently been shown to be mutated in a subset of human glioblastoma samples (48,57). *Trp53* encodes the p53 protein that acts as a regulator of cell cycle arrest and apoptosis. The human gene for p53 (*Trp53*) is mutated in the disease Li-Fraumeni syndrome in which patients are at an increased risk for developing many types of cancer, including brain tumors. *Trp53* or other members of the p53-signaling pathway are frequently mutated in human astrocytoma and glioblastoma samples. Both *Nf1* and *Trp53* have been mutated in mice. Homozygous mutation of *Nf1* is embryonic, lethal and heterozygous mutation of *Nf1* is tumor-prone (8,32). Homozygous mutants for *Trp53* develop thymic lymphoma with high penetrance, whereas heterozygous mutants develop a variety of tumor types, primarily sarcomas (18,31). When *Nf1* and *Trp53* mutations are combined on the same chromosome through a germline recombination event, the resulting *Nf1*<sup>-/+</sup>;*Trp53*<sup>-/+</sup>*cis* (*NPcis*) mice develop malignant peripheral nerve sheath tumors and astrocytomas with high penetrance (11,75).

Studies of the *NPcis* mouse model on different strain backgrounds have demonstrated the importance of genetic risk factors in astrocytoma and glioblastoma, as well as the complexity of interactions between different types of risk factors. *NPcis* mice on a C57BL/6J (B6) strain background are highly susceptible to astrocytomas and glioblastomas, with up to 70% of males developing brain tumors (Table 1). In contrast, *NPcis* mice on a 129S4/SvJae (129S4) strain background are highly resistant to developing astrocytoma and glioblastoma, with as few as 12% of females developing brain tumors (Table 1). In addition to the effect of strain background, the inheritance of the *NPcis* mutant chromosome from the mother or father has an effect on astrocytoma risk. In the case of females, progeny of *NPcis* mutant mothers develop higher-grade tumors than progeny of mutant fathers, although the percentage of the population with brain tumors is the same. In the case of males, progeny of *NPcis* mutant mothers develop more tumors than progeny of mutant fathers (Table 1). This data demonstrates that there is a parent-of-origin effect on brain tumors, likely because of changes in expression of an imprinted gene on mouse chromosome 11. Interestingly, this imprinted effect has gender-specific consequences, with females developing higher-grade tumors and males developing more brain tumors in the population.

Studies are ongoing to map the modifier loci responsible for the difference in susceptibility between the B6 and 129S4 strains. However, comparisons between F1 intercrosses of *NPc1s* mice on a 129S4 background and *NPc1s* mice on the B6 background have identified a modifier locus on mouse chromosome 11 in a 30-Mb congenic region surrounding the *Trp53* and *Nf1* mutations (61). It is interesting to note that there are strain-specific differences in the expression level of *Nf1* in the brain on the B6 and 129S4 strain backgrounds (27). It is therefore possible that levels of *Nf1* expression in the heterozygous brain cell, before the wild-type (WT) copy of *Nf1* is lost, could alter the risk of developing astrocytoma. Further studies are necessary to confirm or disprove this possibility. In addition, there are multiple candidate genes in the region that are polymorphic between B6 and 129S4, and could be responsible for a change in brain tumor risk (61).

In addition to using the *NPc1s* mouse model to identify genetic risk factors for brain tumors, the model has also been used to examine genetic risk factors for malignant peripheral nerve sheath tumors [genetically engineered murine peripheral nerve sheath tumors (GEM PNSTs), in mouse (71)] (Figure 3) (62). These studies have been very informative on the complexity of genetic interactions contributing to nervous system tumor risk, and are shaping the design of experiments to understand risk of brain tumors. The risk of GEM PNSTs is also affected by inheritance of the *NPc1s* mutant chromosome from the mother or the father. In contrast to what is seen with brain tumors, the progeny of mutant fathers have an increased incidence of GEM PNSTs compared to the progeny of mutant mothers (Table 2), with males having a greater risk of GEM PNSTs than females regardless of the cross. Crosses of *NPc1s* B6 mice to the A/J strain have demonstrated the existence of dominant resistance alleles in A/J and backcross mapping has been used to identify loci responsible for resistance to GEM PNSTs. Two nerve sheath tumor resistance loci, *Nstr1* and *Nstr2*, have been identified thus far (62), and the ability of these loci to affect tumor resistance is cross specific. *Nstr1* on mouse chromosome 19 only appears to affect tumor resistance in progeny of *NPc1s* mutant fathers, whereas *Nstr2* on mouse chromosome 15 appears to affect tumor resistance only in progeny of *NPc1s* mutant mothers. When the combined population of progeny of mutant fathers and progeny of mutant mothers were examined for resistance loci, no significant loci were found. This is due to the fact that because the resistance loci only act in a subset of the population, the other unaffected individuals mask the ability to identify significant linkage. The heterogeneity of the population, even within this well-defined mouse population, prevents the identification of genetic risk factors that are present in the population. This further illustrates the difficulties for identifying genetic risk factors directly in patient populations, where the degree of heterogeneity is far greater.

## IDENTIFYING MOUSE GENETIC RISK FACTORS FOR CANCER IN THE 21ST CENTURY

Since the sequencing of the human (38,65,74) and mouse genomes (39,50,76,78) at the beginning of this century, there has been a rapid acceleration in the ability to map genetic risk factors.

These efforts have led to the identification of vast numbers of single nucleotide polymorphisms for following genetic variability in both human and mouse, and made possible the genome-wide association studies currently underway in patient populations (59). In parallel, new research tools being developed in the mouse genetics community are expected to provide new power to identifying genetic risk factors in mice.

Thus far, most of the modifiers of cancer identified in mice have been found through a combination of mapping in backcross populations, intercross populations (Figure 4), recombinant congenic strains as well as candidate gene approaches

(7,12,13,19,21,55,64,84,85). These approaches take advantage of the relative simplicity of comparing two strains through different genomic combinations to find regions of the genome responsible for determining cancer risk. These approaches face the challenges of needing to genotype a large number of mice at a large number of genetic loci in order to correlate the change in phenotype to a particular genotype at a particular point in the genome. Although the ability to genotype large numbers of loci is becoming less costly, efforts have been made to develop strain tools that are fixed in their genotype and therefore do not require genotyping for each experiment performed. These include recombinant inbred strain panels and chromosome substitution strains (Figure 5) (52,70). These panels have the advantage that they are genetically stable and so can be compared across different experiments. As an example, if one found certain strain affected one kind of brain tumor, one could easily go back the these strains and test for effects on other types of brain tumors. More advanced strain tools are now being employed to further balance the need for a simple, experimentally tractable system with the need to increase the heterozygosity of the system to improve mapping resolution [see (28) for a recent review].

Because most mapping of genetic risk factors in mouse focuses on the comparison between two inbred strains, there are limitations to the number of modifiers that can be identified. Despite the differences between the inbred strains, there is relatively low allelic diversity between strains (63). This is because of the fact that the laboratory inbred strains were developed only recently, thus their evolutionary history is short. To address this issue, mouse geneticists are developing an expanded panel of recombinant inbred lines, termed the Collaborative Cross, which is derived from eight different founder strains (10,72). The eight founder strains were chosen for genetic and phenotypic diversity between different strains and subspecies, allowing for the capture of close to 90% of the existing variation in the mouse genome (63) (Figure 5). Through a collaboration of three different breeding locations, up to 1000 independent Collaborative Cross lines are planned and currently being generated (9,30,49). These lines will be densely genotyped, such that by comparing phenotypes across many lines one can map modifiers precisely. Modeling of the distribution of allelic frequency in the Collaborative Cross suggests that it closely mimics the distribution found in the human population (63). This resource should allow a system genetics approach to understanding genetic risk to disease, and allow researchers to examine interactions at multiple loci in a controlled way.

Characterized strains of wild-type mice do not develop spontaneous brain tumors with high enough frequency or short enough latency to provide a tractable experimental system for mapping genetic risk factors. It is therefore important to choose appropriate genetically engineered mouse models for mapping studies. Mouse models on well-defined strain backgrounds can be crossed into backcross or intercross mapping designs (Figure 4) by maintaining the engineered mutations at each generation, or can be crossed to genetic reference panels such as shown in Figure 5 to look at F1 hybrids for genetic risk factors that act dominantly over the strain background of the brain tumor model. These experiment are best performed with “one-allele/one-generation” models. These are models in which the brain tumor phenotype can be observed in the heterozygous state, and either require the inheritance of only one engineered allele, or in which multiple alleles can be homozygosed in a parental line and crossed to the reference panels to examine the phenotype in heterozygotes. Mouse model systems in which many engineered alleles need to be combined, such as in the case for many Cre-flox models, will be difficult to use for mapping studies because of the low rate of co-inheritance of multiple alleles in mouse crosses. Several mouse models are available that fit the one allele/one generation criteria, shown in Table 3, although not all of these may be currently available on an inbred strain background. The *NPcis* model acts as a one-allele model, because although two genes are mutated in the model, they are tightly linked on the same chromosome and so are inherited as a single

allele. Inbred mouse models can be directly crossed to genotyped genetic reference panels to determine the location of modifier loci without further genotyping, since all of the genotypes of the progeny can be inferred from the parents.

It is highly likely that mouse models using different driver mutations leading to brain cancer will identify different genetic risk factors, since different tumor initiating events may be modified by different factors. It will therefore be important to interpret findings in mouse models according to subtypes of human brain tumors. Careful characterization of mouse models of brain tumors will be important, so that findings can be validated in the most relevant subpopulation of human brain tumors. The Cancer Genome Atlas is characterizing human glioblastomas at the molecular level and will help to better align human glioblastoma subpopulations with the closest available mouse model. As an example, recent studies have found that a subset of glioblastomas carry mutations in *NF1* (48,57) and genetic risk loci identified in the *NPcis* mouse model (61) may be most relevant in patients with this subset of tumors. As discussed above, attempts to validate results from specific mouse models across the entire human population may fail because of the swamping out of specific subpopulation effects.

### “... A PIGMY AND A PATAGONIAN, A MOUSE AND A MAMMOTH ...”

Thomas Jefferson noted in his “Notes on the State of Virginia” (33) that although animals of different shapes and sizes had much in common, “... all the manna in heaven would never raise the Mouse to the bulk of the Mammoth.” Although there is much to learn from comparisons of mouse models and human brain tumors to better understand risk factors, it is clear there will be species-specific risk factors that cannot be discovered in model systems. Due to differences in metabolism, mice may respond to dietary and environmental risk factors differently than humans. The differences in the size of the mouse and its lifespan mean that mouse brain tumors are in some ways intrinsically different from human brain tumors. Nonetheless, studies of cancer in mice have demonstrated that many of the fundamental pathways are the same as in humans. It is important to note that mouse models provide a way of getting at some of the fundamental mechanisms underlying genetic risk using a more controlled experimental system. An understanding of these mechanisms can then guide studies in humans toward more focused questions. As an example, one may be able to define different genetic subgroups in the human population and use these subgroups to then examine the effects of environmental factors or diet. It will therefore be important to approach the understanding of risk for brain tumors from both human genome wide association studies, with the clear strengths of looking for strong effects on brain tumors in the human population, and from mouse complex trait studies, with the strengths of being able to isolate different variables and use a more controlled systems genetics approach to understand more complex genetic interactions.

## IMPLICATIONS FOR UNDERSTANDING RISK FACTORS FOR BRAIN TUMORS

It has been recently recommended by the American Academy of Pediatrics that children between the ages of 2 and 10 be screened for high cholesterol, and that children with high cholesterol modify diet, lifestyle or take medications to lower cholesterol and reduce the risk of cardiovascular disease (14). This recommendation received a lot of media attention (56), both positive and negative, and it highlights how in very common diseases, such as heart disease and diabetes, medical research has been able to identify risk factors and implement early screening and early intervention in patient populations. It remains to be seen over the next generation how effective these interventions are at lowering the incidence of common diseases in the population. The ability to screen and intervene early depends on an

understanding of the mechanism underlying the increased risk. By studying brain tumor risk in both humans and mice, it is hoped that markers of increased risk can be identified to facilitate early screening and that the mechanism can be understood to allow for intervention and reduction of risk.

## REFERENCES

1. Ahlbom A, Feychting M, Cardis E, Elliott P. Re: cellular telephone use and cancer risk: update of a nationwide Danish cohort study. *J Natl Cancer Inst.* 2007; 99:655. author reply -6. [PubMed: 17440169]
2. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. *Oncogene.* 2005; 24:7475–7481. [PubMed: 16288294]
3. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. The *NFI* locus encodes a protein functionally related to mammalian GAP and yeast *IRA* proteins. *Cell.* 1990; 63:851–859. [PubMed: 2121371]
4. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science.* 1999; 286:2528–2531. [PubMed: 10617473]
5. Bethke L, Sullivan K, Webb E, Murray A, Schoemaker M, Auvinen A, et al. The common D302H variant of *CASP8* is associated with risk of glioma. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:987–989. [PubMed: 18398042]
6. Bethke L, Webb E, Murray A, Schoemaker M, Johansen C, Christensen HC, et al. Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. *Hum Mol Genet.* 2008; 17:800–805. [PubMed: 18048407]
7. Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, et al. Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus *Pctr2* and can act as a tumor suppressor gene. *Proc Natl Acad Sci USA.* 2003; 100:14982–14987. [PubMed: 14634209]
8. Brannan C, Perkins A, Vogel K, Ratner N, Nordlund M, Reid S, et al. Targeted disruption of the neurofibromatosis type 1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. *Genes Dev.* 1994; 8:1019–1029. [PubMed: 7926784]
9. Chesler EJ, Miller DR, Branstetter LR, Galloway LD, Jackson BL, Philip VM, et al. The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. *Mamm Genome.* 2008; 19:382–389. [PubMed: 18716833]
10. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. *Nat Genet.* 2004; 36:1133–1137. [PubMed: 15514660]
11. Cichowski K, Shih T, Schmitt E, Santiago S, Reilly K, McLaughlin M, et al. Mouse models of tumor development in neurofibromatosis type I. *Science.* 1999; 286:2172–2176. [PubMed: 10591652]
12. Cormier R, Hong K, Halberg R, Hawkins T, Richardson P, Mulherkar R, et al. Secretory phospholipase *Pla2g2a* confers resistance to intestinal tumorigenesis. *Nat Genet.* 1997; 17:88–91. [PubMed: 9288104]
13. Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, et al. *Rrp1b*, a new candidate susceptibility gene for breast cancer progression and metastasis. *PLoS Genet.* 2007; 3:e214. [PubMed: 18081427]
14. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. *Pediatrics.* 2008; 122:198–208. [PubMed: 18596007]
15. de Andrade M, Barnholtz JS, Amos CI, Adatto P, Spencer C, Bondy ML. Segregation analysis of cancer in families of glioma patients. *Genet Epidemiol.* 2001; 20:258–270. [PubMed: 11180451]
16. Dietrich W, Lander E, Smith J, Moser A, Gould K, Luongo C, et al. Genetic identification of *Mom-1*, a major modifier locus affecting *Min*-induced intestinal neoplasia in the mouse. *Cell.* 1993; 75:631–639. [PubMed: 8242739]




17. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. *Cancer Res.* 2001; 61:3826–3836. [PubMed: 11325859]
18. Donehower L, Harvey M, Slagle B, McArthur M, Montgomery C Jr, Butel J, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. *Nature.* 1992; 356:215–221. [PubMed: 1552940]
19. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. *Nat Genet.* 2003; 34:403–412. [PubMed: 12881723]
20. Friedman, JM.; Gutmann, DH.; MacCollin, M.; Riccardi, VM. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 3rd edn.. Johns Hopkins University Press; Baltimore: 1999.
21. Gould K, Luongo C, Moser A, McNeley M, Borenstein N, Shedlovsky A, et al. Genetic evaluation of candidate genes for the *Mom1* modifier of intestinal neoplasia in mice. *Genetics.* 1996; 144:1777–1785. [PubMed: 8978063]
22. Gutmann D, Wood D, Collins F. Identification of the neurofibromatosis type 1 gene product. *Proc Natl Acad Sci USA.* 1991; 88:9658–9662. [PubMed: 1946382]
23. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. *Cancer Res.* 2004; 64:7794–7800. [PubMed: 15520185]
24. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot's syndrome. *N Engl J Med.* 1995; 332:839–847. [PubMed: 7661930]
25. Hardell L, Carlberg M, Soderqvist F, Hansson Mild K. Meta-analysis of long-term mobile phone use and the association with brain tumours. *Int J Oncol.* 2008; 32:1097–1103. [PubMed: 18425337]
26. Hattori S, Maekawa M, Nakamura S. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21. *Oncogene.* 1992; 7:481–485. [PubMed: 1549362]
27. Hawes JJ, Tuskan RG, Reilly KM. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. *Neurogenetics.* 2007; 8:121–130. [PubMed: 17216419]
28. Hunter KW, Crawford NP. The future of QTL mapping to diagnose disease in mice in the age of whole-genome association studies. *Annu Rev Genet.* 2008 Epub ahead of print.
29. Huson, S.; Hughes, R. The Neurofibromatoses: A pathogenetic and Clinical Overview. Chapman & Hall Medical; London: 1994.
30. Iraqi FA, Churchill G, Mott R. The Collaborative Cross, developing a resource for mammalian systems genetics: a status report of the Wellcome Trust cohort. *Mamm Genome.* 2008; 19:379–381. [PubMed: 18521666]
31. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in *p53*-mutant mice. *Current Biology.* 1994; 4:1–7. [PubMed: 7922305]
32. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. *Nat Genet.* 1994; 7:353–361. [PubMed: 7920653]
33. Jefferson, T. Notes on the State of Virginia. 1787. Available at: <http://etext.lib.virginia.edu/modeng/modengJ.browse.html> (accessed September 22, 2008)
34. Kan P, Simonsen SE, Lyon JL, Kestle JR. Cellular phone use and brain tumor: a meta-analysis. *J Neurooncol.* 2008; 86:71–78. [PubMed: 17619826]
35. Kiuru A, Lindholm C, Heinavaara S, Ilus T, Jokinen P, Haapasalo H, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. *J Neurooncol.* 2008; 88:135–142. [PubMed: 18330515]
36. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. *Hum Mol Genet.* 2005; 14:R251–258. Spec No. 2. [PubMed: 16244323]
37. Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2005; 14:1784–1790. [PubMed: 16030117]

38. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001; 409:860–921. [PubMed: 11237011]
39. Lindblad-Toh K, Winchester E, Daly MJ, Wang DG, Hirschhorn JN, Laviolette JP, et al. Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. *Nat Genet*. 2000; 24:381–386. [PubMed: 10742102]
40. Malkin D. *p53* and the Li-Fraumeni syndrome. *Biochim Biophys Acta*. 1994; 1198:197–213. [PubMed: 7819275]
41. Malmer B, Iselius L, Holmberg E, Collins A, Henriksson R, Gronberg H. Genetic epidemiology of glioma. *Br J Cancer*. 2001; 84:429–434. [PubMed: 11161412]
42. Malmer B, Henriksson R, Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. *Int J Cancer*. 2003; 106:260–263. [PubMed: 12800203]
43. Malmer B, Feychting M, Lonn S, Ahlbom A, Henriksson R. *p53* Genotypes and risk of glioma and meningioma. *Cancer Epidemiol Biomarkers Prev*. 2005; 14:2220–2223. [PubMed: 16172235]
44. Malmer B, Haraldsson S, Einarsdottir E, Lindgren P, Holmberg D. Homozygosity mapping of familial glioma in Northern Sweden. *Acta Oncol*. 2005; 44:114–119. [PubMed: 15788289]
45. Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, et al. GLIOGENE an International Consortium to Understand Familial Glioma. *Cancer Epidemiol Biomarkers Prev*. 2007; 16:1730–1734. [PubMed: 17855690]
46. Malmer BS, Feychting M, Lonn S, Lindstrom S, Gronberg H, Ahlbom A, et al. Genetic variation in *p53* and *ATM* haplotypes and risk of glioma and meningioma. *J Neurooncol*. 2007; 82:229–237. [PubMed: 17151932]
47. Martin G, Viskochil D, Bollag G, McCabe P, Crosier W, Conroy L, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with *ras* p21. *Cell*. 1990; 63:843–849. [PubMed: 2121370]
48. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogiannakis M, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*. 2008 Epub ahead of print.
49. Morahan G, Balmer L, Monley D. Establishment of “The Gene Mine”: a resource for rapid identification of complex trait genes. *Mamm Genome*. 2008; 19:390–393. [PubMed: 18716834]
50. Mural RJ, Adams MD, Myers EW, Smith HO, Miklos GL, Wides R, et al. A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. *Science*. 2002; 296:1661–1671. [PubMed: 12040188]
51. Muscat JE, Hinsvark M, Malkin M. Mobile telephones and rates of brain cancer. *Neuroepidemiology*. 2006; 27:55–56. [PubMed: 16825795]
52. Nadeau JH, Singer JB, Matin A, Lander ES. Analysing complex genetic traits with chromosome substitution strains [published erratum appears in *Nat Genet* 2000 May]. *Nat Genet*. 2000; 24:221–225. [PubMed: 10700173]
53. O'Neill BP, Blondal H, Yang P, Olafsdottir GH, Sigvaldason H, Jenkins RB, et al. Risk of cancer among relatives of patients with glioma. *Cancer Epidemiol Biomarkers Prev*. 2002; 11:921–924. [PubMed: 12223439]
54. Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. *Clin Cancer Res*. 2004; 10:2618–2625. [PubMed: 15102663]
55. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, et al. *Sipa1* is a candidate for underlying the metastasis efficiency modifier locus *Mtes1*. *Nat Genet*. 2005; 37:1055–1062. [PubMed: 16142231]
56. Parker-Pope, T. Cholesterol screening is urged for young. *New York Times*. 2008. Available at: <http://query.nytimes.com/gst/fullpage.html?res=9503E4DD133FF934A35754C0A96E9C8B63>
57. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science*. 2008; 321:1807–1812. [PubMed: 18772396]
58. Paunu N, Lahermo P, Onkamo P, Ollikainen V, Rantala I, Helen P, et al. A novel low-penetrance locus for familial glioma at 15q23-q26.3. *Cancer Res*. 2002; 62:3798–3802. [PubMed: 12097292]


59. Pennisi E. Breakthrough of the year. Human genetic variation. *Science*. 2007; 318:1842–1843. [PubMed: 18096770]
60. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. *Nat Genet*. 2000; 26:109–113. [PubMed: 10973261]
61. Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, et al. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. *Proc Natl Acad Sci USA*. 2004; 101:13008–13013. [PubMed: 15319471]
62. Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, et al. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. *Cancer Res*. 2006; 66:62–68. [PubMed: 16397217]
63. Roberts A, Pardo-Manuel de Villena F, Wang W, McMillan L, Threadgill DW. The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. *Mamm Genome*. 2007; 18:473–481. [PubMed: 17674098]
64. Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, Csikos T, et al. Ptpnj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. *Nat Genet*. 2002; 31:295–300. [PubMed: 12089527]
65. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature*. 2001; 409:928–933. [PubMed: 11237013]
66. Schuz J, Jacobsen R, Olsen JH, Boice JD Jr, Johansen JK, McLaughlin C. Cellular telephone use and cancer risk: update of a nationwide Danish cohort. *J Natl Cancer Inst*. 2006; 98:1707–1713. [PubMed: 17148772]
67. Schwartzbaum J, Ahlbom A, Malmer B, Lonn S, Brookes AJ, Doss H, et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. *Cancer Res*. 2005; 65:6459–6465. [PubMed: 16024651]
68. Schwartzbaum JA, Ahlbom A, Lonn S, Malmer B, Wigertz A, Auvinen A, et al. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. *Cancer Epidemiol Biomarkers Prev*. 2007; 16:2448–2454. [PubMed: 18006935]
69. Schwartzbaum JA, Ahlbom A, Lonn S, Warholm M, Rannug A, Auvinen A, et al. An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. *Cancer Epidemiol Biomarkers Prev*. 2007; 16:559–565. [PubMed: 17372252]
70. Singer JB, Hill AE, Nadeau JH, Lander ES. Mapping quantitative trait loci for anxiety in chromosome substitution strains of mice. *Genetics*. 2005; 169:855–862. [PubMed: 15371360]
71. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. *Cancer Res*. 2004; 64:3718–3724. [PubMed: 15150133]
72. Threadgill DW, Hunter KW, Williams RW. Genetic dissection of complex and quantitative traits: from fantasy to reality via a community effort. *Mamm Genome*. 2002; 13:175–178. [PubMed: 11956758]
73. Trizna Z, de Andrade M, Kyritsis AP, Briggs K, Levin VA, Bruner JM, et al. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. *Cancer Epidemiol Biomarkers Prev*. 1998; 7:553–555. [PubMed: 9641501]
74. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. *Science*. 2001; 291:1304–1351. [PubMed: 11181995]
75. Vogel K, Klesse L, Velasco-Miguel S, Meyers K, Rushing E, Parada L. Mouse tumor model for neurofibromatosis type 1. *Science*. 1999; 286:2176–2179. [PubMed: 10591653]
76. Wade CM, Kulbokas EJ 3rd, Kirby AW, Zody MC, Mullikin JC, Lander ES, et al. The mosaic structure of variation in the laboratory mouse genome. *Nature*. 2002; 420:574–578. [PubMed: 12466852]

77. Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. *Cancer Res.* 2004; 64:5560–5563. [PubMed: 15313891]
78. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, et al. Initial sequencing and comparative analysis of the mouse genome. *Nature.* 2002; 420:520–562. [PubMed: 12466850]
79. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. *Cancer Res.* 2003; 63:1589–1595. [PubMed: 12670909]
80. Wiemels JL, Wiencke JK, Kelsey KT, Moghadassi M, Rice T, Urayama KY, et al. Allergy-related polymorphisms influence glioma status and serum IgE levels. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:1229–1235. [PubMed: 17548690]
81. Wigertz A, Lonn S, Schwartzbaum J, Hall P, Auvinen A, Christensen HC, et al. Allergic conditions and brain tumor risk. *Am J Epidemiol.* 2007; 166:941–950. [PubMed: 17646205]
82. Xu G, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates *ras* GTPase and complements *ira* mutants of *S. cerevisiae*. *Cell.* 1990; 63:835–841. [PubMed: 2121369]
83. Xu G, O'Connell P, Viskochil D, Cawthorn R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell.* 1990; 62:599–608. [PubMed: 2116237]
84. Youngren KK, Coveney D, Peng X, Bhattacharya C, Schmidt LS, Nickerson ML, et al. The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. *Nature.* 2005; 435:360–364. [PubMed: 15902260]
85. Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. *Proc Natl Acad Sci USA.* 1998; 95:2429–2434. [PubMed: 9482902]




**Figure 1.**

*Astrocytomas in NPcis mice.* **A.** Shows diffuse dysplastic nuclei in a World Health Organization grade (WHO) II astrocytoma. Approximately 40% of astrocytomas observed in *NPcis* mice are WHO II, depending of the genetic background. **B.** Shows an anaplastic astrocytoma in the spinal cord (V). Approximately 50% of astrocytomas observed are WHO III in the brain or spinal cord. Up to 40% of astrocytomas are found in the spinal cord and many are suggestive of a primary spinal cord lesion, as opposed to infiltration from a primary brain tumor. **C.** Shows an aggressive glioblastoma multiforme (GBM) that appears to have exited the brain at the bottom of the panel, broken through the skull (S), and is spreading along the surface of the skull at the top of the panel. **D.,E.** Show examples of diagnostic criteria in *NPcis* astrocytomas. Dysplastic nuclei are seen in all astrocytomas (**D**) with distinctive multinucleated giant cells (arrows) found in up to 15% of astrocytomas, including most WHO IV tumors. WHO III and WHO IV astrocytomas have varying degrees of mitotic activity (**E**). Arrows point at a couple of the mitoses visible in the panel. (**F**) WHO IV GBMs have regions of N. Scale bars indicate 100  $\mu\text{m}$ . V = vertebra; S = skull; N = necrosis.




**Figure 2.**

*Secondary structures found in NPCis astrocytomas.* **A.** Shows an example of satellitosis in which tumor cells form satellite structures around large neurons. An especially distinctive satellitosis pattern is found in up to 7% of observed astrocytomas. **B.** Shows an example of rosette-like structures (\*) in which tumor cells cluster and fan out from a central point. **C.** Shows an example of perivascular structures in which tumor cells line up along blood vessels in close association. **D.** Shows an example of hemorrhage (H) that is found in most GBMs and many of the more aggressive anaplastic astrocytomas. **E.,F.** Show examples of pseudopallisading tumor cells around a central necrotic core (N) that is found in rare cases of GBM. Scale bars indicate 100 μm. H = hemorrhage.




**Figure 3.** Genetically engineered murine peripheral nerve sheath tumors *in* NPcis mice. **A.,B.** SC, DRG and N are indicated for different MPNSTs. **D.** Shows a high magnification field of the spinal nerve root tumor shown in **C.** (box), and the arrow points to a mitotic figure found in the tumor. Scale bars indicate 100  $\mu$ m. SC = spinal cord; DRG = dorsal root ganglion; N = nerve.



**Figure 4.**

Identifying genetic risk factors between susceptible and resistant strains using F2 intercross or backcross designs. To identify a dominant modifier of resistance (*M*), a susceptible strain and a resistant strain are crossed to generate F1 progeny. Germline recombination events in F1 progeny will generate chromosomes that are a mixture of the two strain backgrounds. F1 progeny can be intercrossed to give rise to F2 progeny carrying different recombination events on each chromosome and allowing the possibility of detecting recessive modifiers. Alternatively, F1 progeny can be backcrossed to the strain carrying the recessive allele of the modifier, simplifying the detection of dominant modifiers.





**Figure 5.**

Reference panels for identifying genetic risk factors. Panels of strains with stable genetics and well-characterized genotypes can be used to identify modifier genes. CSS carry one chromosome from one strain (black) on the background of another strain (gold). By examining the phenotype in a CSS line for each autosomal chromosome, the X and Y chromosomes, and the mitochondria, one can isolate which chromosomes give rise to genetic variation in phenotype. Recombinant inbred strains carry different mixtures of two strains (black and gold), with different combinations in each line. By examining a phenotype across a large number of these lines, one can identify which regions of the genome associate with a particular trait. Because there is limited variation between any two inbred strains, higher order heterogeneous stocks have been generated. A recent example of this is the CC in which eight different strains are combined to preserve variability and then inbred to form lines, with each line carrying different combinations of the eight parental lines. CSS = chromosome substitution strains; CC = collaborative cross; RXS = resistant X susceptible recombinant inbred line.

**Table 1**

Variation in astrocytoma incidence in *NPcis* mice depends on strain background.

Cross	Females (%)	Males (%)
<i>NPcis</i> B6 mother × WT B6 father	51	71
WT B6 mother × <i>NPcis</i> B6 father	52	49
WT 129S4 mother × <i>NPcis</i> 129S4 father	12	17

WT = wild-type.

**Table 2**

Variation in genetically engineered murine peripheral nerve sheath tumor incidence in *NPcis* mice depends on parental inheritance.

Cross	Females (%)	Males (%)
<i>NPcis</i> B6 mother × WT B6 father	34	46
WT B6 mother × <i>NPcis</i> B6 father	60	82

WT = wild-type.

**Table 3**

Examples of “one allele/one generation” mouse models for mapping brain tumor genetic risk factors in genetic reference populations.

<b>Mouse model</b>	<b>Brain tumor</b>	<b>Penetrance (%)</b>	<b>Reference</b>
<i>NPcis</i> , B6	Astrocytoma	Up to 70	(61,62)
GFAP-H- <i>Ras</i> <sup>V12</sup>	Astrocytoma	95	(17)
S100 $\beta$ - <i>v-erbB</i>	Oligodendroglioma	63	(79)
ND2: <i>SmoA1</i>	Medulloblastoma	48	(23)